NHLBI Contract Awarded

January 2, 2018 Longevity Biotech Awarded $225K Phase I SBIR Contract from NHLBI/NIH to develop 5A apoA-I Mimetic Peptide for Treatment of Severe Asthma​​​​​Longevity Biotech, Inc. (LBT) has been awarded a contract from the National … Read More

Grant From NMSS

October 27, 2017 Longevity Biotech Awarded Grant From National Multiple Sclerosis Society to Evaluate LBT-3627 as a Novel Drug Candidate for Multiple Sclerosis​​​​​Longevity Biotech, Inc. (LBT) has received an award from the National Multiple Sclerosis … Read More

Hybridtide Patent Granted


October 10, 2017 Longevity Biotech Granted U.S. Patent Covering Hybridtide Platform Technology for Stabilized Peptide TherapeuticsLongevity Biotech, Inc. (LBT) is pleased to announce that the United States Patent and Trademark Office (USPTO) has issued U.S. … Read More